Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen is a small-cap medical technology company, primarily deriving revenue from its AVISE brand testing products used for diagnosis, prognosis, and monitoring of rheumatic diseases. Challenges facing the company include commercial execution risks, payor concentration risks, and regulatory risks; however, we believe the company is well-positioned for long-term growth and expect continued volume and revenue growth despite near-term ASP declines. With a strong focus on expanding territories and achieving positive free cash flow in 2027, we rate Exagen as a Buy with a price target of $8 per share.

Bears say

Exagen is a company with a strong focus on the medical technology sector, specifically in diagnostic testing for autoimmune diseases. However, with a decrease in projected revenue growth in the long term and potential challenges with obtaining adequate reimbursement from third-party payers, the company may face difficulties in achieving profitability. Additionally, its reliance on a single laboratory facility and its significant debt obligations could pose risks in the future.

Exagen Inc (XGN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.